Deutsche Bank assumed coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research note published on Thursday, Benzinga reports. The brokerage issued a buy rating and a $42.00 price objective on the stock.
DCPH has been the topic of several other research reports. ValuEngine downgraded Woodward, Inc.Common Stock from a buy rating to a hold rating in a research note on Tuesday, April 9th. BidaskClub downgraded Weyco Group from a sell rating to a strong sell rating in a research note on Saturday, July 13th. Piper Jaffray Companies cut Cypress Semiconductor from an overweight rating to a neutral rating in a report on Monday, June 3rd. Finally, Zacks Investment Research cut General Finance from a buy rating to a hold rating in a report on Monday, July 15th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $41.00.
Shares of Deciphera Pharmaceuticals stock opened at $20.65 on Thursday. Deciphera Pharmaceuticals has a 12 month low of $18.55 and a 12 month high of $41.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.55 and a current ratio of 9.55. The business’s fifty day simple moving average is $22.74.
In other Deciphera Pharmaceuticals news, CFO Thomas Patrick Kelly sold 2,100 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $25.20, for a total transaction of $52,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 17,250 shares of company stock valued at $403,813. Corporate insiders own 7.02% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC grew its holdings in shares of Deciphera Pharmaceuticals by 1,405.1% in the 4th quarter. Millennium Management LLC now owns 1,246,640 shares of the company’s stock valued at $26,167,000 after acquiring an additional 1,163,815 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Deciphera Pharmaceuticals by 73.6% in the 4th quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock valued at $24,625,000 after acquiring an additional 497,427 shares in the last quarter. Norges Bank bought a new position in shares of Deciphera Pharmaceuticals in the 4th quarter valued at about $6,974,000. Sofinnova Investments Inc. bought a new position in shares of Deciphera Pharmaceuticals in the 4th quarter valued at about $5,572,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Deciphera Pharmaceuticals in the 4th quarter valued at about $4,337,000. Hedge funds and other institutional investors own 58.89% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.